<DOC>
	<DOCNO>NCT02460380</DOCNO>
	<brief_summary>Polycystic Ovary Syndrome ( PCOS ) affect 5 10 % woman reproductive age . It characterize cluster hyperandrogenism , hyperinsulinemia , menstrual dysfunction , hirsutism infertility . Although pathogenesis PCOS unknown , accumulate evidence suggest transform growth factor-β ( TGF-β ) dysregulation may implicate . TGF-β prototype member TGF-β superfamily proteins . TGF-βs exert diverse range biological function regulate cell proliferation , angiogenesis , fibroblast activation tissue fibrosis . PCOS ovaries show hallmarks TGF-β upregulation , include increase collagen deposition ovarian stroma theca , support increased vascularity . Consistent , The investigator recently show TGF-β1 increase serum PCOS woman circulate receptor soluble endoglin ( sENG ) decrease , result great TGF-β1 bioavailability . PCOS patient also decrease vitamin D level , vitamin D treatment previously show improve various clinical parameter PCOS woman , include glucose intolerance , hypertension androgen level . Interestingly , vitamin D show decrease TGF-β1 level several disease TGF-β1 elevate , include myelofibrosis . Therefore , investigator hypothesize vitamin D treatment PCOS woman result decrease serum TGF-β1 level concomitant improvement clinical disease parameter . In addition , investigator hypothesize improvement clinical disease parameter correlate change TGF-β1 bioavailability . Our aim present study investigate effect vitamin D treatment serum TGF-β1/sENG level PCOS woman , ass whether change TGF-β1/sENG level follow vitamin D treatment correlate clinical disease woman . For end , PCOS patient vitamin D-deficient treat vitamin D serum level TGF-β1 sENG receptor measure treatment . In addition , clinical disease parameter record 4 month treatment , include serum glucose insulin level , serum androgen level , blood pressure . The propose study aim identify putative link vitamin D TGF-β1 context PCOS , provide novel molecular explanation beneficial clinical effect vitamin D PCOS patient .</brief_summary>
	<brief_title>The Effects Vitamin D Transforming Growth Factor-beta1 Polycystic Ovary Syndrome</brief_title>
	<detailed_description>This study randomize , single blind , placebo-controlled trial evaluate effect vitamin D vitamin D-deficient woman PCOS . 93 reproductive-aged woman diagnose PCOS present Maimonides Medical Center annual check-up October 2013 March 2015 screen vitamin D deficiency ( defined 25 hydroxy-vitaminD [ 25OH-D ] level &lt; 20 ng/mL ) . All participant sign informed consent study approve international review board ( IRB ) Maimonides Medical Center . PCOS diagnose accord Rotterdam Consensus ( ESHRE/ASRM criterion ) , i.e . presence two three criterion : oligo- anovulation , sign clinical hyperandrogenism , and/or biochemical sign hyperandrogenism polycystic ovary ultrasonography exclusion specific identifiable disorder ( thyroid disorder , hyperprolactinemia , congenital adrenal hyperplasia , androgen-secreting tumor , Cushing 's syndrome ) . The investigator include woman age 18 38 year : 1 ) pregnant , postpartum , breastfeeding , 2 ) take vitamin D supplement , metformin hormonal therapy , 3 ) diagnose poor ovarian reserve ( AMH &lt; 1ng/mL ) . Interventions blood collection 68 woman diagnose PCOS vitamin D deficiency enrol . Participants allocate group accord computer-generated list use ratio 2/1 ( Vitamin D/placebo ) . Women allocate vitamin D group receive one capsule 50.000 IU vitamin D3 weekly eight week . The vitamin D supplementation regimen extract Endocrine Society guideline . Women placebo group receive capsule placebo weekly eight week . The placebo prepare Maimonides Medical Center 's pharmacy . To ensure compliance , The investigator call participant weekly remind take pill . Fasting blood sample collect venipuncture start within two week complete treatment ( vitamin D placebo ) . Blood sample allow clot 30 minute room temperature centrifugation 1,200 rpm 10 minute . Serum store -80°C aliquot assay . The assay measure hormone , 25OH-D , TGF-β1 , sENG , AMH : Serum 25OH-D level measure complete treatment . The level determine ADVIA Centaur vitamin D assay ( Siemens Healthcare Diagnostics ) . Dehydroepiandrosterone sulfate ( DHEAS ) , testosterone , sex hormone-binding globulin ( SHBG ) , thyroid-stimulating hormone ( TSH ) , follicle-stimulating hormone ( FSH ) , luteinizing hormone ( LH ) measure use IMMULITE 2000 XPi immunoassay system ( Siemens Healthcare USA ) . Insulin prolactin concentration quantify DXL 800 immunoassay analyzer accord manufacturer 's protocol ( Beckman Coulter ) . Insulin resistance calculate accord homeostatic model assessment ( HOMA ) ( 29 ) use follow formula : Insulin resistance ( HOMA IR ) = [ fasting insulin ( µU/mL ) x fast glucose ( mmol/L ) ] /22.5 . 17OH-progesterone level determine ELISA assay ( Eagle BioSciences ) . AMH concentration measure use ultrasensitive AMH/MIS CLIA kit ( AnshLabs ) . TGF-β1 concentration measure use Human TGF-beta1 Quantikine ELISA kit accord manufacturer 's protocol ( R &amp; D Systems ) . sENG level quantify Human Endoglin/CD105 Quantikine ELISA kit ( R &amp; D Systems ) . The inter-assay intra-assay coefficient variation assay less 10 % . Clinical parameter : All clinical parameter evaluate four month completion treatment . These parameter include blood pressure ( BP ) , Ferriman-Gallwey score ( FGS ) ( hirsutism score ) , acne status , interval period . Statistical analysis : Data test normality . All value express mean ± standard error mean ( SEM ) . A paired student 's t-test use compare pre- post-treatment serum level clinical parameter . Correlation change serum TGF-β1/sENG change clinical disease parameter analyze use Pearson 's test linear regression . X2-test used evaluate change acne treatment . SigmaStat ( SPSS Science , Chicago , IL ) use statistical analysis . P &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Women PCOS vitamin D deficiency ( serum 25hydroxyvitamin D &lt; 20 ng/mL ) Pregnant , postpartum , breast feeding Taking Metformin , vitamin D , hormonal therapy Diagnosed poor ovarian reserve ( AMH &lt; 1ng/mL ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>